FDA's concerns with unapproved GLP-1 drugs

The U.S. Food and Drug Administration (FDA) has issued a response following multiple adverse events linked to unapproved weight loss drugs. Dosing errors related to unapproved drugs have resulted in several hospitalizations, including a few fatalities. Drugs lacking FDA approval have not been reviewed by the agency for safety, effectiveness, or quality—unlike FDA-approved medications … [Read more...] about FDA Responds to Concerns Over Unapproved Weight Loss Drugs